Rein Therapeutics pauses dosing in lung disease trial after US FDA places hold

Rein Therapeutics

12/06/2025 21:34

June 12 (Reuters) - Rein Therapeutics RNTX.O said on Thursday it has paused enrollment and patient dosing in the U.S. after the Food and Drug Administration placed a clinical hold on a mid-stage trial of its lung disease drug.

 (Reporting by Siddhi Mahatole in Bengaluru; Editing by Sahal Muhammed)

 ((siddhi.mahatole@thomsonreuters.com;))